Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapy

Hepatology

Volumn 50, Issue 2, 2009, Pages 654-655

  Hsu, Chiun ^a   Wei, Shu Chen ^a   Cheng, Ann Lii ^a   Chen, Pei Jer ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; RITUXIMAB; TENOFOVIR;

ANTIVIRAL THERAPY; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LYMPHOMA; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; TOXIC HEPATITIS; TREATMENT DURATION; VIRUS MUTATION; VIRUS REACTIVATION; CHEMICALLY INDUCED DISORDER; RECURRENT DISEASE;

HEPATITIS B; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECURRENCE;

EID: 68949172200     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23067     Document Type: Letter

References (6)

1. Kuhbacher T, Fölsch UR. Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol 2007;12:1149-1155.
2. Zeitz J, Mullhaupt B, Fruehauf H, Rogler G, Vavricka S. Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. HEPATOLOGY 2009; doi 10.1002/hep.23035.
3. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit for prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. HEPATOLOGY 2008;47:844-853.
4. Lok ASF, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2007;45:507-539.
5. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. HEPATOLOGY 2006;43:209-220.
6. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605-611.